-
Recall will begin in September 2011 to allow sufficient time for patients to be switched to suitable alternatives.
-
Supporting safer use
-
Suspension of the licences (marketing authorisations) for Octagam (intravenous human normal immunoglobulin 5% and 10%) lifted.
-
Use restricted to adults with advanced or metastatic breast cancer only.
-
Increased risk of arterial thromboembolism, including myocardial infarction and cerebrovascular events for patients treated with thalidomide.
-
Updated dosing for paediatric paracetamol liquids has been developed to ensure children receive the optimum dose for their age.
-
A reminder to healthcare professionals to fill out Yellow Card reports.
-
Risk of venous thromboembolism (VTE) for drospirenone-containing combined oral contraceptives (COCs), including Yasmin, is higher than for levonorgestrel-containing COCs.
-
Atypical femoral fractures reported rarely with bisphosphonate therapy, mainly in patients receiving long-term treatment for osteoporosis.
-
Risks of Nicobrevin outweigh any benefits.
-
Healthcare professionals should be aware of this risk when prescribing prasugrel.
-
Reminder to monitor and manage weight, glucose, and lipid levels.
-
Use only when other antibiotics are unsuitable
-
Where possible, use an appropriate alternative therapy for patients at increased risk of thrombosis.
-
Stavudine should only be used when there are no appropriate alternatives, and for the shortest possible time.
-
Further information is available to support safer use
-
Risk of developing progressive multifocal leukoencephalopathy (PML) associated with natalizumab is increased in patients who have had previous immunosuppressant therapy.
-
Prescribers should be vigilant for possible thrombotic adverse reactions.
-
Patients receiving lenalidomide for management of multiple myeloma should be closely monitored for evidence of arterial and venous thromboembolic events.
-
Risk of aseptic peritonitis with Dianeal, Extraneal, and Nutrineal peritoneal dialysis solutions due to possible presence of endotoxin.
-
If eosinophilic pneumonia is suspected, daptomycin should be discontinued immediately and if appropriate the patient treated with corticosteroids.
-
If pioglitazone is used in combination with insulin patients should be observed for signs and symptoms of heart failure, weight gain, and oedema.
-
(Dextro)propoxyphene can have serious effects on the electrical activity of the heart (resulting in prolongation of the P-R and Q-T intervals, and widened QRS complexes), even at normal therapeutic doses.
-
Dental examination and appropriate preventive dentistry should be considered before treatment with bevacizumab or sunitinib.
-
-
Use in pelvic inflammatory disease only when other antibacterials are inappropriate or ineffective.
-
Sitaxentan (Thelin▼) withdrawn due to hepatotoxicity.
-
No evidence of increased risk of febrile convulsions in children.
-
Saquinavir at a reduced dose for the first week of treatment
-
Differences in dose delivery between the pump device and dropper device for memantine.
-
Safety studies of Spiriva Respimat▼
-
Drug interactions involving CYP2D6, genetic variants, and variability in clinical response
-
Insufficient evidence to confirm a link between oral bisphosphonate use and an increased risk of oesophageal cancer.
-
Report of febrile promptly.
-
All healthcare professionals trained in inserting Implanon must make sure they are trained in using Nexplanon before the changeover.
-
Second year safety review
-
Suspension of the marketing authorisations of rosiglitazone (Avandia, Avandamet) recommended across the European Union.
-
Should not be used for cough under 18 years
-
Outline of the safety experience of these medicines in the UK from our proactive safety monitoring strategy.
-
Prescribers should remain vigilant with regards to the similarity of these 2 drug names.
-
Benefits of these medicines used in conjunction with inhaled corticosteroids (ICS) in the control of asthma symptoms in children outweigh any apparent risks.
-
Check pumps after MRI.
-
Risk of psychological and behavioural side effects.
-
Update on managing risk of misuse.
-
Erythema multiforme, Stevens Johnson syndrome and toxic epidermal necrolysis reported in association with isotretinoin - may result in hospitalisation, disability, life-threatening events, or death.
-
Aluminium can be leached from glass after contact with calcium gluconate solution, leading to a risk of exposure to aluminium. Accumulation of aluminium might have adverse effects on bone mineralisation and neurological deve…
-
European Medicines Agency has recommends the use of modafinil should be restricted to treat only sleepiness associated with narcolepsy - should no longer be used for obstructive sleep apnoea or chronic shift work sleep disor…
-
European Medicines Agency says further measures should be put in place to minimise the risk of adverse skin reactions.
-
Patients should be transferred to alternative bronchodilator therapy.
-
Risk of accidental overdose, particularly in infants and neonates.